| Ident. | Authors (with country if any) | Title |
|---|
| 000109 |
Omar Ouachikh [France] ; Wisam Dieb [France] ; Franck Durif [France] ; Aziz Hafidi [France] | Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area |
| 000502 |
Santiago Perez-Lloret [France, Argentine] ; Olivier Rascol [France] | Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's Disease |
| 000646 |
N. Cabedo [Espagne] ; I. Berenguer [Espagne] ; B. Figadere [France] ; D. Cortes [Espagne] | An Overview on Benzylisoquinoline Derivatives with Dopaminergic and Serotonergic Activities |
| 000930 |
J.-C. Corvol [France] ; J.-A. Girault [France] ; D. Herve [France] | Rôle et régulation du récepteur D1 de la dopamine dans le striatum : implications dans les dyskinésies de la maladie de Parkinson |
| 000978 |
Stéphane Thobois [France] | Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease : A review of the literature |
| 000A11 |
Yuri Bozzi [Italie] ; Emiliana Borrelli [France] | Dopamine in neurotoxicity and neuroprotection : what do D2 receptors have to do with it? |
| 000B76 |
R. Bordet [France] | Les récepteurs dopaminergiques centraux (Partie II): Implications physiopathologiques et thérapeutiques |
| 000C12 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000C16 |
Stéphane Thobois [France, Royaume-Uni] ; Francois Vingerhoets [Suisse] ; Valerie Fraix [France] ; Jing Xie-Brustolin [France] ; Hélène Mollion [France] ; Nicolas Costes [France] ; Patrick Mertens [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] ; Emmanuel Broussolle [France] | Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease. A positron emission tomographic study |
| 000C85 |
F. Ghawche [France] ; F. Durif [France] | Traitement dopaminergique et syndromes parkinsoniens |
| 000D41 |
R. Bordet [France] ; D. Devos [France] ; S. Brique [France] ; Y. Touitou [France] ; J. D. Guieu [France] ; C. Libersa [France] ; A. Destee [France] | Study of circadian melatonin secretion pattern at different stages of Parkinson's disease |
| 000D70 |
Olivier Rascol [France] ; Pierre Payoux [France, Portugal] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France] | Limitations of current Parkinson's disease therapy. Discussion |
| 000D80 |
Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study |
| 000E14 |
| Parkinson et mouvements anormaux |
| 000E28 |
A. Destee [France] ; R. Bordet [France] | Stimulation dopaminergique continue, stimulation dopaminergique pulsatile |
| 000E32 |
J. L. Montastruc [France] ; O. Rascol [France] | Propriétés pharmacodynamiques des agonistes dopaminergiques ? Quelle transférabilité en pratique clinique dans le traitement de la maladie de Parkinson ? |
| 000E46 |
A. Nieoullon [France] ; M. Amalric [France] | Les récepteurs dopaminergiques : aspects structuraux et implications fonctionnelles |
| 000E49 |
A.-M. Bonnet [France] ; J.-L. Houeto [France] | Le pergolide: un agoniste utile dans le traitement de la maladie de Parkinson |
| 000E63 |
F. Durif [France] | Fluctuations motrices |
| 000E92 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
| 000F63 |
C. Lebrun-Frenay [France] ; M. Borg [France] | Choosing the right dopamine agonist for patients with Parkinson's disease |
| 000F80 |
K. Ray Chaudhuri [Royaume-Uni] ; Suvankar Pal [Royaume-Uni] ; Christine Brefel-Courbon [France] | 'Sleep attacks' or 'Unintended sleep episodes' occur with dopamine agonists: Is this a class effect? |
| 001077 |
Olivier Rascol [France] ; Nelly Fabre [France] | Dyskinesia: L-dopa-induced and tardive dyskinesia |
| 001080 |
Thomas Boraud [France] ; Erwan Bezard [France] ; Bernard Bioulac [France] ; Christian E. Gross [France] | Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey |
| 001084 |
S. Thobois [France] ; S. Guillouet [France] ; E. Broussolle [France] | Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease |
| 001085 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 001114 |
P. Derkinderen [France] | Stratégies thérapeutiques conseillées à la phase initiale de la maladie |
| 001181 |
J. J. Ferreira [France, Portugal] ; M. Galitzky [France] ; J. L. Montastruc [France] ; O. Rascol [France] | Sleep attacks and Parkinson's disease treatment |
| 001216 |
H. Allain [France] ; A. Destee [France] ; H. Petit [France] ; M. Patay [France] ; S. Schück [France] ; D. Bentue-Ferrer [France] ; P. Le Cavorzin [France] | Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease |
| 001231 |
C. Warren Olanow [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] | Continuous dopamine-receptor stimulation in early Parkinson's disease |
| 001233 |
C. Imbert [France] ; E. Bezard [France] ; S. Guitraud [France] ; T. Boraud [France] ; C. E. Gross [France] | Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey |
| 001264 |
C. Brefel-Courbon ; O. Rascol | Scintigraphies cérébrales et syndromes parkinsoniens |
| 001282 |
G. L. Defer [France] | Controverse sur le traitement initial de la maladie de parkinson : L-dopa ou agonistes dopaminergiques ? |
| 001283 |
O. Rascol [France] | Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques |
| 001286 |
M. Ziegler [France] ; P. Rondot [France] | Activité du piribédil dans la maladie de Parkinson : Etude multicentrique |
| 001290 |
J. L. Montastruc [France] ; O. Rascol [France] ; J.-M. Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 001344 |
O.-K. Hassani [France] ; J. Feger [France] | Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats : An electrophysiological and C-fos study |
| 001373 |
J.-L. Montastruc [France] ; M. Ziegler [France] ; O. Rascol [France] ; M. Malbezin [France] | A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
| 001435 |
P. Hantraye [France] | Modeling dopamine system dysfunction in experimental animals |
| 001481 |
| CONTROLE DOPAMINERGIQUE DU NOYAU SYBTHALAMIQUE CHEZ LE RAT NORMAL ET CHEZ LE RAT MODELE DE LA MALADIE DE PARKINSON (RATS 6-OHDA) |
| 001555 |
E. Courty [France] ; F. Durif [France] ; M. Zenut [France] ; P. Courty [France] ; J. Lavarenne [France] | Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease |
| 001582 |
F. Coudore [France] ; F. Durif [France] ; E. Duroux [France] ; A. Eschalier [France] ; J. Fialip [France] | Effect of tolcapone on plasma and striatal apomorphine disposition in rats |
| 001618 |
P. Morel [France] | Les perspectives thérapeutiques de la maladie de Parkinson |
| 001653 |
F. Tison [France] ; L. Wiart [France] ; M. Guatterie [France] ; N. Fouillet [France] ; V. Lozano [France] ; P. Henry [France] ; M. Barat [France] | Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease |
| 001740 |
D. Muguet [France] ; E. Broussolle ; G. Chazot | Apomorphine in patients with Parkinson's disease : Parkinson's disease |
| 001867 |
F. Durif [France] ; M. Paire [France] ; D. Deffond [France] ; A. Eschalier [France] ; G. Dordain [France] ; M. Tournilhac [France] ; J. Lavarenne [France] | Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease |
| 001A04 |
J. L. Montastruc [France] | Recent advances in the clinical pharmacology of Parkinson's disease |
| 001A31 |
H. Allain ; D. Bentueê-Ferrer ; J. L. Merot ; R. Decombe | Pharmacologie des agonistes dopaminergiques |
| 001B18 |
P. Celsis ; O. Rascol ; J. F. Demonet ; A. Agniel ; J. L. Montastruc ; J. P. Marc-Vergnes ; A. Rascol | Effet de la bromocriptine sur le débit sanguin cérébral dans la maladies de Parkinson |
| 001B80 |
P. Hantraye ; B. Maziere ; M. Maziere ; H. Fukuda ; R. Naquet | Dopaminergic and benzodiazepine receptors studied in vivo by PET |
| 001B83 |
P. Hantraye ; C. Loc'H ; U. Tacke ; D. Riche ; O. Stulzaft ; D. Doudet ; B. Guibert ; R. Naquet ; B. Maziere ; M. Maziere | "In vivö visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates |
